查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590857

移植物抗宿主疾病治療市場：按疾病類型、產品類型和最終用戶分類 - 2025-2030 年全球預測

Graft Versus Host Disease Treatment Market by Disease Type (Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease), Product (Corticosteroids, Monoclonal Antibodies, Tyrosine Kinase Inhibitors), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

移植物抗宿主疾病治療市場2023年估值為18.7億美元，預計2024年將達20.6億美元，複合年成長率為10.45%，2030年將達37.6億美元，預計將達到1000萬美元。

移植物抗宿主疾病（GVHD）治療通常涉及旨在減弱移植後供體來源的免疫細胞攻擊受體身體組織時的免疫反應的藥物和治療方法。這些治療方法在確保移植成功和患者存活（尤其是骨髓和幹細胞移植患者）方面的關鍵作用凸顯了對這些治療方法的需求。應用範圍包括皮質類固醇、TNF 抑制劑等藥物和針對急性和慢性 GVHD 症狀的新型生物製藥。最終用途主要是在醫院和專科移植中心，由能夠管理複雜治療方法的熟練醫療保健專業人員提供支援。這個市場主要是由移植手術數量的增加、先進的診斷以及新型免疫抑制療法的研究和開發的增加所推動的。基因組技術和生物標記發現的進步正在吸引人們對個人化醫療和精準免疫療法的關注，從而實現量身定做的治療。生物技術公司之間的策略聯盟、增加的醫療保健資金和監管支援將促進產品創新和市場進入。

主要市場統計
基準年[2023] 18.7億美元
預測年份 [2024] 20.6億美元
預測年份 [2030] 37.6億美元
複合年成長率（%） 10.45%

挑戰包括先進治療方法的高成本、監管障礙以及與現有免疫抑制藥物相關的副作用，這些副作用可能導致繼發性感染和惡性。此外，疾病機制的複雜性對開發普遍有效的治療方法構成了主要障礙。 GVHD 發病的可預測性和症狀的有限變異性需要更具適應性的治療方法，並且很難將臨床結果與患者需求相匹配。

創新研究領域包括精確調節免疫反應的 CRISPR 等基因編輯技術、基於微生物的治療方法的開發以及使用 CAR-T 和 Tregs 增強細胞療法。市場本質上是動態的，傾向於採用個人化、技術主導的方法來有效地解決未滿足的需求。因此，企業可以透過專注於策略夥伴關係關係、以患者為中心的臨床試驗和技術整合來抓住潛在的業務成長機會，以推動有效的產品開發，同時克服挑戰。

市場動態：揭示快速發展的移植物抗宿主疾病治療市場的關鍵市場見解

供需的動態交互作用正在改變移植物抗宿主疾病治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 由於航空貨運收入和噸位增加，大件和重型貨物增加
    • 同種異體移植數量的增加
    • 接受異體造血幹細胞移植的患者數量不斷增加
  • 市場限制因素
    • 數位化造成的破壞以及加快全球貨物運輸的要求
    • 與其他交通工具的競爭
    • 治療方法的臨床進展
  • 市場機會
    • 新興市場貨運服務的成長
    • 新飛機技術數位化的技術發展
  • 市場挑戰
    • 貿易緊張局勢和行業監管收緊

波特的五力戰略工具駕馭移植物抗宿主疾病治療市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解移植物抗宿主疾病治療市場的外部影響

外部宏觀環境因素在塑造移植物抗宿主疾病治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解移植物抗宿主疾病治療市場的競爭格局

移植物抗宿主疾病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV定位矩陣移植物抗宿主疾病治療市場供應商績效評估

FPNV 定位矩陣是評估移植物抗宿主疾病治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了移植物抗宿主疾病治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，移植物抗宿主疾病治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 航空貨運收入和負載容量的增加增加了對大件和重型貨物的需求
      • 同種異體移植的增加
      • 接受異體造血幹細胞移植的患者數量不斷增加
    • 抑制因素
      • 數位化和加速全球貨物流動的需求造成的破壞
      • 與其他交通途徑的競爭
      • 治療程序的臨床進展
    • 機會
      • 新興市場貨運服務的成長
      • 新型飛機技術與數位化技術開發
    • 任務
      • 貿易緊張局勢及產業監管加強
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章移植物抗宿主疾病治療市場：依疾病類型

  • 急性移植物抗宿主疾病
  • 慢性移植物抗宿主疾病

第7章移植物抗宿主疾病治療市場：依產品

  • 皮質類固醇
  • 單株抗體
  • 蛋白酪氨酸激酶抑制劑

第8章移植物抗宿主疾病治療市場：依最終用戶分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章 美洲移植物抗宿主疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太移植物抗宿主疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的移植物抗宿主疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • ElsaLys Biotech SA
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt LLC
  • Merck KGaA
  • Mesoblast Limited
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Ocugen, Inc.
  • Pfizer Inc
  • Pluristem Therapeutics Inc.
  • Sanofi SA
  • Soligenix, Inc.
Product Code: MRR-43676CF42284

The Graft Versus Host Disease Treatment Market was valued at USD 1.87 billion in 2023, expected to reach USD 2.06 billion in 2024, and is projected to grow at a CAGR of 10.45%, to USD 3.76 billion by 2030.

Graft Versus Host Disease (GVHD) treatment typically encompasses pharmaceuticals and therapies aimed at attenuating the immune response when donor-derived immune cells attack the recipient's body tissue post-transplant. The necessity of these treatments is underscored by their critical role in ensuring transplant success and patient survival, especially in bone marrow and stem cell transplant patients. The application spans a range of pharmaceuticals like corticosteroids, TNF inhibitors, and novel biologics, targeting both acute and chronic GVHD manifestations. End-use scope prominently features hospitals and specialized transplant centers, backed by skilled healthcare professionals capable of handling complex treatment regimens. The market is primarily driven by rising transplantation procedures, advanced diagnostics, and increased R&D for novel immunosuppressive therapies. Emerging opportunities focus on personalized medicine and precision immunotherapies, aided by advances in genomic technologies and biomarker discovery, allowing tailored treatment pathways. Strategic collaboration between biotech firms, increased healthcare funding, and regulatory support enhances product innovation and market reach.

KEY MARKET STATISTICS
Base Year [2023] USD 1.87 billion
Estimated Year [2024] USD 2.06 billion
Forecast Year [2030] USD 3.76 billion
CAGR (%) 10.45%

Challenges include the high cost of advanced therapies, regulatory hurdles, and side effects associated with existing immunosuppressants, which can contribute to secondary infections and malignancies. Additionally, the complexity of disease mechanisms poses significant barriers in developing universally efficacious treatments. Limited predictability of GVHD onset and variability of symptoms necessitate more adaptive therapeutic approaches, presenting hurdles in aligning clinical outcomes with patient needs.

Innovative research areas include gene editing technologies like CRISPR to modulate immune responses precisely, development of microbiome-based therapies, and enhanced cellular therapies using CAR-T and Tregs. The market, inherently dynamic, gravitates towards adopting personalized and technology-driven approaches to address unmet needs efficiently. Therefore, companies should focus on strategic partnerships, patient-centric trials, and technology integration to drive effective product development while navigating challenges, offering potential business growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Graft Versus Host Disease Treatment Market

The Graft Versus Host Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
    • Growing number of allogeneic transplantations
    • Rising number of patients undergoing allogeneic haematopoietic stem cell transplants
  • Market Restraints
    • Disruption through digitization and demand to speed-up the movement of goods across the globe
    • Competition from other transport modes
    • Clinical advancements in the treatment procedure
  • Market Opportunities
    • Growth of cargo services in emerging markets
    • Technological developments in new aircraft technologies and the digitization
  • Market Challenges
    • Trade tensions and increasing industry regulation

Porter's Five Forces: A Strategic Tool for Navigating the Graft Versus Host Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Graft Versus Host Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Graft Versus Host Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Graft Versus Host Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Graft Versus Host Disease Treatment Market

A detailed market share analysis in the Graft Versus Host Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Graft Versus Host Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Graft Versus Host Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Graft Versus Host Disease Treatment Market

A strategic analysis of the Graft Versus Host Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graft Versus Host Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, Johnson & Johnson Services, Inc., Mallinckrodt LLC, Merck KGaA, Mesoblast Limited, Neovii Pharmaceuticals AG, Novartis AG, Ocugen, Inc., Pfizer Inc, Pluristem Therapeutics Inc., Sanofi S.A., and Soligenix, Inc..

Market Segmentation & Coverage

This research report categorizes the Graft Versus Host Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Acute Graft Versus Host Disease and Chronic Graft Versus Host Disease.
  • Based on Product, market is studied across Corticosteroids, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors.
  • Based on End-User, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
      • 5.1.1.2. Growing number of allogeneic transplantations
      • 5.1.1.3. Rising number of patients undergoing allogeneic haematopoietic stem cell transplants
    • 5.1.2. Restraints
      • 5.1.2.1. Disruption through digitization and demand to speed-up the movement of goods across the globe
      • 5.1.2.2. Competition from other transport modes
      • 5.1.2.3. Clinical advancements in the treatment procedure
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth of cargo services in emerging markets
      • 5.1.3.2. Technological developments in new aircraft technologies and the digitization
    • 5.1.4. Challenges
      • 5.1.4.1. Trade tensions and increasing industry regulation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Graft Versus Host Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Acute Graft Versus Host Disease
  • 6.3. Chronic Graft Versus Host Disease

7. Graft Versus Host Disease Treatment Market, by Product

  • 7.1. Introduction
  • 7.2. Corticosteroids
  • 7.3. Monoclonal Antibodies
  • 7.4. Tyrosine Kinase Inhibitors

8. Graft Versus Host Disease Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Graft Versus Host Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Graft Versus Host Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Graft Versus Host Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. ElsaLys Biotech SA
  • 5. Johnson & Johnson Services, Inc.
  • 6. Mallinckrodt LLC
  • 7. Merck KGaA
  • 8. Mesoblast Limited
  • 9. Neovii Pharmaceuticals AG
  • 10. Novartis AG
  • 11. Ocugen, Inc.
  • 12. Pfizer Inc
  • 13. Pluristem Therapeutics Inc.
  • 14. Sanofi S.A.
  • 15. Soligenix, Inc.

LIST OF FIGURES

  • FIGURE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GRAFT VERSUS HOST DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ACUTE GRAFT VERSUS HOST DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CHRONIC GRAFT VERSUS HOST DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023